---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-410663"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-10-01T20:08:04+00:00"
generated_at: "2026-10-12T14:22:22.775192+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics (CATX) files updated corporate presentation covering four 212Pb radiopharmaceutical programs

## Summary
- Perspective Therapeutics filed an updated corporate presentation (Exhibit 99.1) dated October 1, 2026, signed by CFO Joel Sendek.
- Presentation cites a combined $45B+ addressable solid tumor market for VMT-α-NET, VMT01, PSV359 and PSV594.
- VMT-α-NET Phase 1/2a data in SSTR2+ neuroendocrine tumors targeted for ASCO 2026; safety data shown for 68 treated patients.
- VMT01 preliminary anti-tumor activity observed at the 3.0 mCi dose in melanoma; PSV359 shows improved tumor retention against FAP-α.
- CCK2R81 is highlighted as a potential first-in-class agent in medullary thyroid cancer and selected solid tumors.

## SEC filing metadata
- accession: 0001193125-26-410663
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-10-01T20:08:04+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/0001193125-26-410663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000119312526410663/catx-20261001.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-410663
- JSON: https://secwatch.observer/filing/0001193125-26-410663.json
- Plain text: https://secwatch.observer/filing/0001193125-26-410663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.